Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,postMarketChangePercent,postMarketTime,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2021) 4","Short Ratio (Jul 14, 2021) 4","Short % of Float (Jul 14, 2021) 4","Short % of Shares Outstanding (Jul 14, 2021) 4","Shares Short (prior month Jun 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,GNPX,49812149,47363700,2169143,,-6489713,,-6489713,4316310,0,-6491695,-6491695,,,,,,0,0,6491695,0,1982,,-6489713,-6489713,610696,115287472,613626,50422845,274658,51036471,47315,3107900,-64911942,10741,47068703,613626,37300,50377734,127,338968,146493.0,-110030.0,25324330.0,199958.0,25324330.0,19749018.0,-5465282.0,6242.0,671738.0,-91701.0,,49764108,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,0.95000005,0.42410716,2.24 - 7.72,-4.5299997,-0.5867875,2.24,7.72,1589486400,1589486400,1589486400,-0.473,0.05,-0.5,3.17,-0.01999998,1.26984,3.062 - 3.23,3.15,0.0,0.0,8,9,finmb_225557674,NasdaqCM,"Genprex, Inc.",USD,573393,346757,-6.38,1.066,2.9332857,0.25671434,0.08751767,3.8275723,-0.6375723,-0.16657354,151090208,63.8,2.9924953,15,America/New_York,EDT,-14400000,4,-0.62695867,1630530320,NCM,PREPRE,us_market,"Genprex, Inc.",3.19,1630526402,0.03999996,3.12,3.23,3.062,286128,-0.95,,,7.72,2.24,2.9333,3.8276,573.39k,346.76k,47.36M,,39.78M,10.55%,17.14%,2.79M,3.76,6.19%,5.90%,3.71M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-31.18%,-50.74%,,,,,-18.85M,-18.87M,-0.4730,,47.07M,0.99,,,82.10,1.07,-14.88M,-12.36M,Value,78746,Healthcare,12,10,10,"Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.",Austin,877 774 4679,TX,8,1609372800,1625097600,10,United States,http://www.genprex.com,86400,10,3300 Bee Cave Road,Biotechnology,Suite 650-227
t-1,GNPX,30314865,47363700,2319393,,-5228314,,-5228314,2904331,0,-5229658,-5229658,,,,,,0,0,5229658,0,1344,,-5228314,-5228314,601625,89295601,450724,30916490,257756,31367214,43118,3011042,-58422229,10741,27319685,450724,39441,30715407,127,192968,-132456.0,-2341665.0,12495016.0,789079.0,12495016.0,6261299.0,-3892052.0,5934.0,673747.0,-3035.0,-42.0,30264683,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,0.95000005,0.42410716,2.24 - 7.72,-4.5299997,-0.5867875,2.24,7.72,1589486400,1589486400,1589486400,-0.473,0.05,-0.5,3.17,-0.01999998,1.26984,3.062 - 3.23,3.15,0.0,0.0,8,9,finmb_225557674,NasdaqCM,"Genprex, Inc.",USD,573393,346757,-6.38,1.066,2.9332857,0.25671434,0.08751767,3.8275723,-0.6375723,-0.16657354,151090208,63.8,2.9924953,15,America/New_York,EDT,-14400000,4,-0.62695867,1630530320,NCM,PREPRE,us_market,"Genprex, Inc.",3.19,1630526402,0.03999996,3.12,3.23,3.062,286128,-0.95,,,7.72,2.24,2.9333,3.8276,573.39k,346.76k,47.36M,,39.78M,10.55%,17.14%,2.79M,3.76,6.19%,5.90%,3.71M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-31.18%,-50.74%,,,,,-18.85M,-18.87M,-0.4730,,47.07M,0.99,,,82.10,1.07,-14.88M,-12.36M,Value,78746,Healthcare,12,10,10,"Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.",Austin,877 774 4679,TX,8,1609372800,1625097600,10,United States,http://www.genprex.com,86400,10,3300 Bee Cave Road,Biotechnology,Suite 650-227
t-2,GNPX,22388329,47363700,1350016,,-2774943,,-2774943,1421863,0,-2777593,-2777593,,,,,,0,0,2777593,0,2650,,-2774943,-2774943,587712,76130492,375655,22976041,54231,23351696,39464,686324,-53193915,10741,21058386,375655,42340,22710903,85,321424,139457.0,152719.0,793647.0,166789.0,793647.0,-1068793.0,-2015159.0,5714.0,447824.0,-1767.0,-42.0,22335248,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,0.95000005,0.42410716,2.24 - 7.72,-4.5299997,-0.5867875,2.24,7.72,1589486400,1589486400,1589486400,-0.473,0.05,-0.5,3.17,-0.01999998,1.26984,3.062 - 3.23,3.15,0.0,0.0,8,9,finmb_225557674,NasdaqCM,"Genprex, Inc.",USD,573393,346757,-6.38,1.066,2.9332857,0.25671434,0.08751767,3.8275723,-0.6375723,-0.16657354,151090208,63.8,2.9924953,15,America/New_York,EDT,-14400000,4,-0.62695867,1630530320,NCM,PREPRE,us_market,"Genprex, Inc.",3.19,1630526402,0.03999996,3.12,3.23,3.062,286128,-0.95,,,7.72,2.24,2.9333,3.8276,573.39k,346.76k,47.36M,,39.78M,10.55%,17.14%,2.79M,3.76,6.19%,5.90%,3.71M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-31.18%,-50.74%,,,,,-18.85M,-18.87M,-0.4730,,47.07M,0.99,,,82.10,1.07,-14.88M,-12.36M,Value,78746,Healthcare,12,10,10,"Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.",Austin,877 774 4679,TX,8,1609372800,1625097600,10,United States,http://www.genprex.com,86400,10,3300 Bee Cave Road,Biotechnology,Suite 650-227
t-3,GNPX,23974990,47363700,2155637,,-4373293,,-4373293,2216691,0,-4378104,-4378104,,,,,,0,0,4378104,0,4811,,-4373293,-4373293,534523,74889855,239786,24509513,57819,24749299,38630,893999,-50418972,10741,22127179,239786,46287,24157748,85,181967,-456425.0,-11291.0,2569226.0,-1056941.0,2569226.0,-952412.0,-3510347.0,5776.0,2370621.0,-1350.0,-85.0,23917962,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,0.95000005,0.42410716,2.24 - 7.72,-4.5299997,-0.5867875,2.24,7.72,1589486400,1589486400,1589486400,-0.473,0.05,-0.5,3.17,-0.01999998,1.26984,3.062 - 3.23,3.15,0.0,0.0,8,9,finmb_225557674,NasdaqCM,"Genprex, Inc.",USD,573393,346757,-6.38,1.066,2.9332857,0.25671434,0.08751767,3.8275723,-0.6375723,-0.16657354,151090208,63.8,2.9924953,15,America/New_York,EDT,-14400000,4,-0.62695867,1630530320,NCM,PREPRE,us_market,"Genprex, Inc.",3.19,1630526402,0.03999996,3.12,3.23,3.062,286128,-0.95,,,7.72,2.24,2.9333,3.8276,573.39k,346.76k,47.36M,,39.78M,10.55%,17.14%,2.79M,3.76,6.19%,5.90%,3.71M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-31.18%,-50.74%,,,,,-18.85M,-18.87M,-0.4730,,47.07M,0.99,,,82.10,1.07,-14.88M,-12.36M,Value,78746,Healthcare,12,10,10,"Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.",Austin,877 774 4679,TX,8,1609372800,1625097600,10,United States,http://www.genprex.com,86400,10,3300 Bee Cave Road,Biotechnology,Suite 650-227
